Stay updated on Mirikizumab Maintenance Study in Ulcerative Colitis Clinical Trial
Sign up to get notified when there's something new on the Mirikizumab Maintenance Study in Ulcerative Colitis Clinical Trial page.

Latest updates to the Mirikizumab Maintenance Study in Ulcerative Colitis Clinical Trial page
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page's revision label updated from v3.6.4 to v3.6.5, indicating a new build/version of the Record History interface. This update reflects an updated version of the page software.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page history shows a new revision tag (v3.6.4) in place of the previous revision (v3.6.3). This indicates a minor update to the page's revision metadata.SummaryDifference0.0%

- Check52 days agoChange DetectedA new revision entry v3.6.3 was added to the study history, and the previous revision v3.6.2 was removed, updating the page's version history.SummaryDifference0.0%

- Check59 days agoChange DetectedThe Record History now shows Revision: v3.6.2, replacing v3.6.0, indicating an update to the page's underlying build rather than any trial-related information.SummaryDifference0.0%

- Check73 days agoChange DetectedThe recruitment status is updated to 'No longer looking for participants', indicating enrollment is closed for the study. The revision history shows the record updated to 'Revision: v3.6.0' from the previous 'Revision: v3.5.5'.SummaryDifference0.1%

- Check80 days agoChange DetectedThe revision history now includes a new revision tag v3.5.5. The previous tag v3.5.4 has been removed, updating the page's version history to reflect a minor maintenance change rather than any study data update.SummaryDifference0.0%

Stay in the know with updates to Mirikizumab Maintenance Study in Ulcerative Colitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirikizumab Maintenance Study in Ulcerative Colitis Clinical Trial page.